Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Xenon Pharmaceuticals Inc. (XENE)

35.38   0.35 (1%) 09-27 11:35
Open: 35.13 Pre. Close: 35.03
High: 35.545 Low: 34.97
Volume: 84,810 Market Cap: 2,269(M)

Technical analysis

as of: 2023-09-27 11:20:51 AM
Short-term rate:       
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Mid-term rate:       
Target: Six months: 44.45     One year: 46.87
Support: Support1: 34.7    Support2: 28.87
Resistance: Resistance1: 38.05    Resistance2: 40.13
Pivot: 36.52
Moving Average: MA(5): 35.3     MA(20): 37.19
MA(100): 38.8     MA(250): 37.63
MACD: MACD(12,26): -0.8     Signal(9): -0.5
Stochastic oscillator: %K(14,3): 9.4     %D(3): 9.2
RSI: RSI(14): 34
52-week: High: 43.75  Low: 31.79
Average Vol(K): 3-Month: 320 (K)  10-Days: 353 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ XENE ] has closed above bottom band by 20.0%. Bollinger Bands are 3.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 35.94 - 36.14 36.14 - 36.3
Low: 34.09 - 34.37 34.37 - 34.6
Close: 34.62 - 35.03 35.03 - 35.37

Company Description

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other potential indications, including adult focal epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop PCRX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Headline News

Mon, 25 Sep 2023
DNB Asset Management AS Has $4.34 Million Holdings in Xenon ... - MarketBeat

Fri, 22 Sep 2023
RBC Capital Reiterates Xenon Pharmaceuticals (XENE) Outperform ... - Nasdaq

Sat, 16 Sep 2023
Xenon Pharmaceuticals (NASDAQ:XENE) Upgraded by StockNews ... - MarketBeat

Tue, 12 Sep 2023
Xenon Pharmaceuticals Announces Upcoming Investor Webinar ... - GlobeNewswire

Wed, 30 Aug 2023
Oppenheimer & Co. Inc. Invests $451000 in Xenon Pharmaceuticals ... - MarketBeat

Wed, 09 Aug 2023
Xenon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update - Yahoo Finance

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 64 (M)
% Held by Insiders 5.901e+007 (%)
% Held by Institutions 0.6 (%)
Shares Short 2,650 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.843e+008
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -141
Return on Assets (ttm) 10.6
Return on Equity (ttm) -15.6
Qtrly Rev. Growth 132000
Gross Profit (p.s.) 0
Sales Per Share -17.06
EBITDA (p.s.) -7.18881e+007
Qtrly Earnings Growth -2.5
Operating Cash Flow 0 (M)
Levered Free Cash Flow -131 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio -0.3
Price to Book value 0
Price to Sales -2.07
Price to Cash Flow 4.65

Stock Dividends

Dividend 0
Forward Dividend 2.78e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.